Istituto Oncologico Veneto IRCCS

• Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  Phase 1, Not yet recruiting, 14 people, Oct 30, 2026

• NCT06275919

  Phase 2, Recruiting, 104 people, Feb 23, 2024

• NCT06155279

  Phase 2, Active, not recruiting, 41 people, Dec 4, 2023

• Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients

  Phase 1, Completed, 21 people, Oct 23, 2023

• Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion

  Collaborator, Phase 2, Completed, 110 people, Sep 13, 2023

• NCT04659551

  Phase 2, Completed, 43 people, Dec 9, 2020

• NCT04656262

  Phase 3, Terminated, 79 people, Dec 7, 2020

• NCT04224441

  Collaborator, Phase 2, Status unknown, 41 people, Jan 13, 2020

• NCT02926222

  Phase 2, Completed, 119 people, Oct 6, 2016

• NCT02926196

  Phase 3, Completed, 474 people, Oct 6, 2016

• NCT02511639

  Phase 3, Completed, 110 people, Jul 30, 2015

Sources: clinicaltrials.gov